Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 49-57

  Kang, Hee E ^a,b   Sohn, Se I ^c   Baek, Seung R ^c   Lee, Jee W ^a   Lee, Myung G ^a,b  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

acute renal failure; liquiritigenin; pharmacokinetics; UDPGA; UGT

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; LIQUIRITIGENIN; LIQUIRITIGENIN 4' O GLUCURONIDE; LIQUIRITIGENIN 7 O GLUCURONIDE; UNCLASSIFIED DRUG; URANYL NITRATE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; INTESTINE; KIDNEY CLEARANCE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; NONHUMAN; PLASMA PROTEIN BINDING; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ACUTE KIDNEY INJURY; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; FLAVANONES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; INFUSIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; URANYL NITRATE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 78650405921     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01175.x     Document Type: Article

References (37)

1. Kim SC, et al. Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). Toxicology 2004; 197: 239-251.
2. Kim YW, et al. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. Chem Biol Interact 2006; 161: 125-138.
3. Kim YW, et al. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. Am J Physiol Gastrointest Liver Physiol 2009; 296: G372-G381.
4. Shimamura H, et al. Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: an analysis based on metabolite kinetics. Biol Pharm Bull 1993; 16: 899-907.
5. Shimamura H, et al. Biliary and urinary metabolites of liquiritigenin in rats. Jpn J Pharmacogn 1990; 44: 265-268.
6. Kang HE, et al. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect. Xenobiotica 2009; 39: 465-475.
7. Kang HE, et al. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up. J Pharm Sci 2009; 98: 4327-4342.
8. Kang HE, et al. Pharmacokinetic interaction between liquiritigenin (LQ) and DDB: increased glucuronidation of LQ in the liver possibly due to increased hepatic blood flow rate by DDB. Eur J Pharm Sci 2010; 39: 181-189.
9. 4. Xenobiotica 2010; 40: 424-436.
10. Kang HE, et al. Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5′-diphosphoglucuronic acid level. Metabolism 2010. doi:10.1016/j.metabol. 2010.01.012. [Epub ahead of print].
11. Wu CC, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006; 65: 28-33.
12. Kim SH, et al. Acute hepatitis A-associated acute renal failure in adults. Nephron Clin Pract 2008; 109: c127-c132.
13. Jung YJ, et al. Clinical features of acute renal failure associated with hepatitis A virus infection. J Viral Hepatol 2010; 17: 611-617.
14. Mesquita M, et al. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol 2008; 70: 69-71.
15. Martin P, Fabrizi F,. Hepatitis C virus and kidney disease. J Hepatol 2008; 49: 613-624.
16. Kamar N, et al. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69: 149-160.
17. Perico N, et al. Hepatitis C infection and chronic renal diseases. Clin. J Am Soc Nephrol 2009; 4: 207-220.
18. Lee MG, et al. Pharmacokinetic changes of drugs in rat model of acute renal failure induced by uranyl nitrate: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Curr Clin Pharmacol 2006; 1: 193-205.
19. Moon YJ, et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
20. Choi YH, et al. Slower clearance of intravenous metformin in rats with acute renal failure induced by uranyl nitrate: contribution of slower renal and non-renal clearances. Eur J Pharm Sci 2010; 39: 1-7.
21. Mitruka BM, Rawnsley HM,. Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd edn. New York: Masson Publishing, 1981.
22. Lee JH, Lee MG,. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 2008; 25: 1915-1924.
23. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
24. Watkins JB, Klaassen CD,. Determination of hepatic uridine 5′-diphosphoglucuronic acid concentration by conjugation with diethylstilbestrol. J Pharmacol Methods 1982; 7: 145-151.
25. Fisher MB, et al. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000; 28: 560-566.
26. Duggleby RG,. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.
27. Yamamura N, et al. Panipenum, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos 2000; 28: 1484-1486.
28. Boudinot FD, Jusko WJ,. Fluid shifts and other factors affecting plasma protein-binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-780.
29. Øie S, Guentert TW,. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 1982; 71: 127-128.
30. Kang HE, et al. Determination of an agent for the inflammatory liver disease, liquiritigenin, in rat plasma, urine, and various tissue homogenates by high-performance liquid chromatography. Proceedings of the Spring International Convention of the Pharmaceutical Society of Korea. International Convention Center, Jeju, South Korea, April 30-May 3, 2008; Abstract p. 342.
31. Almási A, et al. A simple and rapid ion-pair HPLC method for simultaneous quantitation of 4-nitrophenol and its glucuronide and sulfate conjugates. J Biochem Biophys Methods 2006; 69: 43-50.
32. Gibaldi M, Perrier D,. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, Inc., 1982.
33. Chiou WL,. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
34. Hursh JB, Spoor NL,. Data on man. In:, Hodge HC, et al., eds. Uranium, Plutonium, Transplutonic Elements. New York: Springer-Verlag, 1973: 197-240.
35. Wilkinson GR, Shand DG,. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
36. Yu C, et al. Effect of chronic renal insufficiency on hepatic and renal UDP-glucuronyltransferases in rats. Drug Metab Dispos 2006; 34: 621-627.
37. Katayama H, et al. Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. J Pharmacobiodyn 1984; 7: 536-544.